Evidence map›Paper›PMID 40995140›Full record

ArticleOncology letters2025

ARHGEF6 downregulation as a key mediator of tumor cell apoptosis in breast cancer.

Yang Zhang, Dandan Zhou, Xuting Shen, Qinqin Song, Liuyang Yang, Wenbo Li, Xinxin Zhao, Wenxiang Fang, Bian Liu, Chencen Xing and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yang ZhangDepartment of Central Laboratory, The Third People's Hospital of Bengbu Affiliated to Bengbu Medical University, Bengbu, Anhui 233000, P.R. China.
Dandan ZhouDepartment of Critical Care Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, P.R. China.
Xuting ShenDepartment of Pathophysiology, Anhui Medical University, Hefei, Anhui 230032, P.R. China.
Qinqin SongDepartment of Burn and Plastic Surgery, The Third People's Hospital of Bengbu Affiliated to Bengbu Medical University, Bengbu, Anhui 233000, P.R. China.
Liuyang YangDepartment of Central Laboratory, The Third People's Hospital of Bengbu Affiliated to Bengbu Medical University, Bengbu, Anhui 233000, P.R. China.
Wenbo LiDepartment of Central Laboratory, The Third People's Hospital of Bengbu Affiliated to Bengbu Medical University, Bengbu, Anhui 233000, P.R. China.
Xinxin ZhaoCore Facility Center for Medical Sciences, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230001, P.R. China.
Wenxiang FangAnimal Experiment Center, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230001, P.R. China.
Bian LiuDepartment of Central Laboratory, The Third People's Hospital of Bengbu Affiliated to Bengbu Medical University, Bengbu, Anhui 233000, P.R. China.
Chencen XingDepartment of Medical Education, The Fifth People's Hospital of Bengbu, Bengbu, Anhui 233000, P.R. China.
Jisong LiuDepartment of Burn and Plastic Surgery, The Third People's Hospital of Bengbu Affiliated to Bengbu Medical University, Bengbu, Anhui 233000, P.R. China.
Haoshu FangDepartment of Pathophysiology, Anhui Medical University, Hefei, Anhui 230032, P.R. China.
Qilun ZhangDepartment of Central Laboratory, The Third People's Hospital of Bengbu Affiliated to Bengbu Medical University, Bengbu, Anhui 233000, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study aimed to identify novel clinical biomarkers for breast cancer (BRCA) through bioinformatics analyses and cellular experiments, due to the ongoing need for improved diagnosis and prognosis in BRCA. The GSE21422 and The Cancer Genome Atlas-BRCA (TCGA-BRCA) datasets were utilized to identify differentially expressed genes (DEGs) in BRCA. Common DEGs were subjected to comprehensive analyses, including risk score modeling, expression profiling, receiver operating characteristic curve evaluation, survival analysis and the development of a prognostic nomogram, to pinpoint clinically significant genes. Cellular assays were subsequently performed to investigate the functional roles of these key genes in BRCA. Through bioinformatics analyses, 5 genes with diagnostic value were identified: Aldehyde dehydrogenase 1 family member A1 (ALDH1A1), Rac/Cdc42 guanine nucleotide exchange factor 6 (ARHGEF6), enhancer of zeste 2 polycomb repressive complex 2 subunit, integrin α1 (ITGA1) and PIK3R1, as well as 3 genes with prognostic value: ALDH1A1, ARHGEF6 and ITGA1. Among them, ARHGEF6 was recognized as the key gene in BRCA. Overexpression of ARHGEF6 was shown to suppress cell proliferation, invasion and migration, while promoting apoptosis in BRCA. In conclusion, by bioinformatics analysis, new diagnostic and prognostic biomarkers for patients with BRCA have been identified and the key gene, ARHGEF6, is a suppressor gene in BRCA progression. These findings provide new directions for BRCA clinical application.

Indexed as

biomarkersbreast cancerdiagnosisprognosisRac/Cdc42 guanine nucleotide exchange factor 6

Identifiers

PMID40995140
PMCPMC12455277

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.